HOUSE 4242118th CongressReferred to the Subcommittee on Health.

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.

Last Action: 6/23/2023

Actions

2023-06-23Referred to the Subcommittee on Health.
2023-06-21Referred to the House Committee on Energy and Commerce.
2023-06-21Introduced in House
2023-06-21Introduced in House

CRS Summary

As of 2023-06-21 (00)

This bill requires the Food and Drug Administration (FDA) to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy, including how to request support from the FDA for related investigational use exemptions.

Cosponsors (2)

Mariannette Miller-Meeks (R-IA)
Ro Khanna (D-CA)

Subjects

Administrative law and regulatory procedures
Alternative treatments
Department of Health and Human Services
Drug therapy
Drug, alcohol, tobacco use
Medical research

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.